Amgen's Fourier trial for Repatha met its primary composite endpoint and the key secondary composite endpoint.
Repatha is a drug for reducing the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease. The primary endpoint for the study involved whether the drug could reduce chances of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina or coronary revascularization.
The key secondary composite endpoint involved whether the drug could reduce cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. According to Amgen, it observed no new safety issues during the study.
"In the Glagov study, we demonstrated that Repatha has an effect on atherosclerosis, the underlying cause of cardiovascular disease," Dr. Sean Harper, executive vice president of Research and Development at Amgen, said in a statemement. "These Fourier results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy. Cardiovascular disease remains the No. 1 health burden in the world, and we look forward to sharing these outcomes data with the scientific community."